Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single‐arm, open‐label study

Documents similaires

• Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
  par: Christian Pfrepper, et autres
  Publié: (2024)
• Is pharmacological thromboprophylaxis necessary in persons with haemophilia undergoing major orthopaedic surgery?
  par: Silvia Linari, et autres
  Publié: (2024)
• Emicizumab plasma levels after accelerated saturation in acquired haemophilia A
  par: Tristan Kloeter, et autres
  Publié: (2024)
• EAHAD statement on the ISTH clinical practice guideline for treatment of congenital haemophilia A and B
  par: Pratima Chowdary, et autres
  Publié: (2024)
• Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence
  par: Gili Kenet, et autres
  Publié: (2024)